Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 7 |
| 1.1 List of Tables | 6 | 3 |
| 1.2 List of Figures | 9 | 2 |
| 2 Global Respiratory Therapeutics Market : Scope of Research | 11 | 1 |
| 2.1 Introduction | 11 | 1 |
| 2.2 GBI Research Report Guidance | 11 | 1 |
| 3 Global Respiratory Therapeutics Market : Market Characteraization | 12 | 11 |
| 3.1 Market Forecasts | 12 | 1 |
| 3.2 Branded Vs Generics | 13 | 1 |
| 3.3 Average Cost of Therapy | 14 | 1 |
| 3.4 Volume | 15 | 1 |
| 3.5 Usage Patterns | 16 | 1 |
| 3.5.1 Diseased Population | 16 | 1 |
| 3.5.2 Treatment Seeking Population | 17 | 1 |
| 3.5.3 Diagnosed Population | 18 | 1 |
| 3.5.4 Prescription Population | 19 | 1 |
| 3.5.5 Usage Patterns | 20 | 2 |
| Global Revenue Distribution Indication Wise | 22 | 1 |
| 4 Global Asthma Therapeutics Market | 23 | 8 |
| 4.1 Market Forecasts | 23 | 1 |
| 4.2 Average Cost of Therapy | 24 | 1 |
| 4.3 Volume | 25 | 1 |
| 4.4 Usage Patterns | 26 | 1 |
| 4.4.1 Diseased Population | 26 | 1 |
| 4.4.2 Treatment Seeking Population | 27 | 1 |
| Diagnosed Population | 28 | 1 |
| 4.4.4 Prescription Population | 28 | 1 |
| 4.4.5 Usage Patterns | 29 | 2 |
| 5 Global COPD Therapeutics Market | 31 | 8 |
| 5.1 Market Forecasts | 31 | 1 |
| 5.2 Average Cost of Therapy | 32 | 1 |
| 5.3 Volume | 32 | 2 |
| 5.4 Usage Patterns | 34 | 1 |
| 5.4.1 Diseased Population | 34 | 1 |
| 5.4.2 Treatment Seeking Population | 35 | 1 |
| 5.4.3 Diagnosed Population | 36 | 1 |
| 5.4.4 Prescription Population | 37 | 1 |
| 5.4.5 Usage Patterns | 37 | 2 |
| Global Pulmonary Arterial Hypertension Therapeutics Market | 39 | 8 |
| 6.1 Market Forecasts | 39 | 1 |
| 6.2 Volume | 40 | 1 |
| 6.3 Average Cost of Therapy | 41 | 1 |
| 6.4 Usage Patterns | 42 | 1 |
| 6.4.1 Diseased Population | 42 | 1 |
| 6.4.2 Treatment Seeking Population | 43 | 1 |
| 6.4.3 Diagnosed Population | 44 | 1 |
| 6.4.4 Prescription Population | 45 | 1 |
| 6.4.5 Usage Patterns | 45 | 2 |
| Global Cystic Fibrosis Therapeutics Market | 47 | 8 |
| 7.1 Market Forecasts | 47 | 1 |
| 7.2 Volume | 48 | 1 |
| 7.3 Average Cost of Therapy | 49 | 1 |
| 7.4 Usage Patterns | 50 | 1 |
| 7.4.1 Diseased Population | 50 | 1 |
| 7.4.2 Treatment Seeking Population | 51 | 1 |
| 7.4.3 Diagnosed Population | 52 | 1 |
| 7.4.4 Prescription Population | 53 | 1 |
| 7.4.5 Usage Patterns | 53 | 2 |
| 8 Global Respiratory Therapeutics Market : Market Drivers and Restraints | 55 | 6 |
| 8.1 Market Drivers | 55 | 1 |
| 8.1.1 Steady Increase in the Smoking Population | 55 | 1 |
| Stable Increase in Incidence Rates for Respiratory Diseases Disorders | 56 | 1 |
| 8.1.3 Increase in Awareness Levels of Disease Progression and Etiology | 56 | 1 |
| 8.2 Market Restraints | 56 | 1 |
| 8.2.1 Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers | 56 | 1 |
| 8.2.2 Reimbursement Restrictions on Drug Classes for Certain Respiratory Diseases Drug Classes Restricts the Market Growth | 57 | 1 |
| 8.3 Global Respiratory Therapeutics Market : Unmet Needs | 57 | 1 |
| 8.4 Global Respiratory Therapeutics Market: Key Market Trends | 58 | 1 |
| 8.5 Increase in Disease Incidence and Prevalence Rates | 59 | 1 |
| 8.6 Product Pipeline | 59 | 1 |
| 8.7 Advertising and Commercialization | 59 | 1 |
| 8.8 Regulatory Trends Current Reimbursement Scenario | 59 | 1 |
| 8.8.1 The Budget Impact on Drug Reimbursements | 60 | 1 |
| 8.8.2 Reliability on Generic Formulations as a Cost Cutting Measure | 60 | 1 |
| Global Respiratory Therapeutics Market: Competitive Landscape | 61 | 4 |
| 9.1 Overview | 61 | 1 |
| 9.2 Market Share Analysis | 61 | 1 |
| 9.3 Competitive Profiling | 62 | 1 |
| 9.3.1 GlaxoSmithKline | 63 | 1 |
| 9.3.2 AstraZeneca | 63 | 1 |
| 9.3.3 Merck | 63 | 1 |
| 9.3.4 Boehringer Ingelheim GmbH | 64 | 1 |
| 10 Global Respiratory Therapeutics Market : Strategic Consolidations | 65 | 8 |
| 10.1 Mergers and Acquisitions | 65 | 1 |
| 10.1.1 Overview | 65 | 2 |
| 10.1.1.1 Reckitt Benckiser-Adams Respiratory | 67 | 1 |
| 10.1.1.2 Pfizer-Encysive Pharmaceuticals | 67 | 1 |
| 10.1.1.3 Novartis-Nektar Therapeutics (Pulmonary Business Unit) | 67 | 1 |
| 10.1.1.4 Critical Therapeutics-Cornerstone Biopharma Holdings | 67 | 1 |
| 10.2 Licensing Agreements | 67 | 2 |
| 10.2.1 Approval | 69 | 1 |
| 10.2.1.1 Alvesco HFA | 69 | 1 |
| 10.2.1.2 Curosurf | 70 | 1 |
| 10.2.2 Filed | 70 | 1 |
| 10.2.2.1 Daxas | 70 | 1 |
| 10.2.2.2 Symbicort | 70 | 1 |
| 10.2.3 Phase III | 70 | 1 |
| 10.2.3.1 Unit Dose Budesonide | 71 | 1 |
| 10.2.3.2 Budesonide | 71 | 1 |
| 10.2.4 Phase II | 71 | 1 |
| 10.2.4.1 AMG317 | 72 | 1 |
| 10.2.4.2 PTC124 | 72 | 1 |
| 10.2.5 Pre-clinical | 72 | 1 |
| 10.2.5.1 AZD1419 | 72 | 1 |
| 10.2.6 Discovery | 72 | 1 |
| 10.2.6.1 La Jolla/Med OX 40 Ligand | 72 | 1 |
| 11 Global Respiratory Therapeutics Market : Appendix | 73 | 6 |
| 11.1 Market Definitions | 73 | 1 |
| 11.2 Abbreviations | 73 | 1 |
| 11.3 Research Methodology | 74 | 5 |
| 11.3.1 Coverage | 74 | 1 |
| 11.3.1.1 Secondary Research | 74 | 1 |
| 11.3.1.2 Forecasts | 75 | 1 |
| 11.3.1.3 Analogous forecasting methodology | 75 | 1 |
| 11.3.1.4 Diseased Population | 75 | 1 |
| 11.3.1.5 Treatment Seeking Population | 76 | 1 |
| 11.3.1.6 Diagnosis Population | 76 | 1 |
| 11.3.1.7 Prescription Population | 76 | 1 |
| 11.3.2 Primary Research | 77 | 1 |
| 11.3.3 Expert Panels | 78 | 1 |
| 11.4 Contact Us | 78 | 1 |
| 11.5 Disclaimer | 78 | 1 |